Coronavirus Disease 2019 (COVID-19) Pipeline of Small and Mid-Cap Bio/Pharma Companies

Scope

This 28-page PowerPoint based report gives an important expert analysis on how the developement of vaccines and therapeutics for COVID-19 has been approached by Small and Mid Cap Bio/Pharma Companies. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Reasons to buy

An overview of how Small and Mid Cap Bio/Pharma Companies have approached the developemnt of vaccines and therapeutics for the COVID-19 pandemic.

Companies mentioned

Sinopharm Group Co Ltd

CanSino Biologics Inc

Novavax Inc

Swedish Orphan Biovitrum AB

Biohaven Pharmaceutical Holding Company Ltd

FibroGen Inc

Cytodyn Inc

Insmed Inc US

Mesoblast Ltd

Humanigen Inc

Vanda Pharmaceuticals Inc

Athersys Inc

Abivax SA

Dynavax Technologies Corp

Vir Biotechnology

Akers Biosciences Inc

InflaRx

Table of Contents

Background

1 COVID-19 Pipeline of Small and Mid-Cap Companies

1.1 COVID-19 Pipeline of Small and Mid-Cap Companies

1. 2 Analysis of COVID-19 Pipeline by Phase and Type

1.3 Analysis of COVID-19 Pipeline by Market Cap

2 Vaccine Development by Small and Mid-Cap Companies

2.1 COVID-19 Vaccine Pipeline by Phase and Molecule Subtype

2.2 Highest Development Phase COVID-19 Vaccine Pipeline

3 Therapeutic Development by Small and Mid-Cap Companies

3.1 COVID-19 Therapeutic Pipeline by Phase and Molecule Type

3.2 COVID-19 Biologic Therapeutic Pipeline by Phase and Molecule Subtype

3.3 Highest Development Phase COVID-19 Therapeutic Pipeline

4 COVID-19 Deals

4.1 COVID-19-related Partnership Agreements with Small and Mid-Cap Companies

4.2 COVID-19-related Licensing Agreements with Small and Mid-Cap Companies

Key Findings

Appendix

6.1 Glossary

6.2 Methodology

6.3 Related Reports

6.4 About the Authors

6.5 About GlobalData

6.6 Contact Us

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports